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In this issue of Cell Host & Microbe, Liu et al. (2015) and Burgess and Mohr (2015) describe how two poxvirus
mRNA decapping enzymes hijack a host 50-to-30-exoribonuclease to evade antiviral innate immunity by
limiting accumulation of double-stranded RNA.A deadly chess game is in progress be-
tween viruses and their hosts that has
extended over millions of years. Higher
vertebrates have evolved elaborate and
multilayered innate immune systems
that, when successful, suppress or other-
wise retard viral infections until the adap-
tive immune system can clear the
infection. As a consequence, to propa-
gate and spread, viruses must counteract
host innate immunity.
Among viral pathogens that infect hu-
mans, the dsDNA genome poxvirus fam-
ily includes one of the deadliest, variola
virus, the causative agent of smallpox.
Prior to development of an effective vac-
cine and its eradication in 1980, variola
virus left a trail of destruction extending
for many thousands of years. However,
for virologists, poxviruses, in particular
the smallpox vaccine strain, vaccinia vi-
rus (VACV), provide a treasure trove of
information on this topic because of their
relatively large genomes (including about
200 genes), the fact that they replicate
entirely in the cytoplasm (where many
innate immunity factors reside), and the
many fascinating ways in which they
counteract host immunity (McFadden,
2005).
To replicate and spread, poxviruses
must antagonize two potent host anti-
viral pathways: the 20,50-oligoadenylate
synthetase (OAS)/RNase L and double-stranded RNA (dsRNA)-dependent pro-
tein kinase R (PKR) systems (Sadler and
Williams, 2008) (Figure 1). Interferons
(IFNs) produced in response to viral infec-
tions induce through cell-surface recep-
tors JAK-STAT signaling, resulting in
transcription of a family of OAS genes
and a single PKR gene. DsRNA produced
by the virus activates both PKR and OAS
proteins. PKR undergoes auto-phosphor-
ylation and then it phosphorylates trans-
lation initiation factor eIF2a, inhibiting
recycling of the GDP-bound form,
causing cessation of protein synthesis.
OAS proteins produce unusual 20-to-50
linked oligoadenylates known as ‘‘2-5A’’
from ATP. 2-5A binds with monomeric
RNase L, causing it to dimerize into a
catalytically active form that internally
cleaves viral and cellular single-stranded
RNA (Dong and Silverman, 1995). There-
fore, both pathways block viral protein
synthesis but by different mechanisms;
one is direct (PKR), and the other is indi-
rect (OAS/RNase L) by degrading mRNA
and rRNA.
It has been known for 46 years that
VACV produces dsRNA from annealing
of complementary strands of viral RNA
late in the poxvirus replication cycle
(Duesberg and Colby, 1969). In perhaps
the most important advance on this topic
since then, back-to-back papers in this
issue of Cell Host & Microbe describehow VACV blunts antiviral responses by
limiting the accumulation of dsRNA
(Burgess and Mohr, 2015; Liu et al.,
2015) (Figure 1). Late (post DNA replica-
tion) in the poxvirus replication cycle,
dsRNA is formed by base-pairing be-
tween converging viral transcripts pro-
duced from opposite strands of the viral
genome. It turns out that VACV prevents
high levels of dsRNA from accumulating
through an RNA catabolic pathway
that borrows from and mimics the host
50-to-30 pathway of mRNA decay (Fig-
ure 1). In eukaryotes, a decapping
enzyme (Dcp2) containing a nudix/MutT
hydrolase motif removes m7-GDP caps
allowing the 50-to-30-exoribonuclease,
Xrn1, to progressively degrade the de-
capped 50-monophosphorylated RNAs
(Jones et al., 2012). VACV D9 and D10
proteins, nudix/MutT motif enzymes, are
involved in suppressing translation of
host mRNA, countering the host antiviral
response while reducing competition for
host translational machinery, and in main-
taining divisions between different stages
(early, intermediate, and late) of the virus-
replication cycle (see Liu et al. [2015] for
original references). D9 and D10 are early
and late proteins, respectively, which
have about 25% sequence identity and
are widely conserved among chordopox-
viruses, highlighting their importance.
However, due to their compensating7, March 11, 2015 ª2015 Elsevier Inc. 287
Figure 1. Poxviruses Antagonize Antiviral Innate Immunity by
Limiting the Accumulation of DsRNA
Late in the vaccinia virus (VACV) replication cycle, complementary,
converging viral transcripts anneal to form dsRNA. However, accumulation
of viral dsRNA is limited due to the combined activities of two viral mRNA de-
capping enzymes (D9 and D10) and the host 50-to-30 exoribonuclease Xrn1.
When D9 and D10 are mutated in the same virus, or when Xrn1 is depleted
with RNAi, viral dsRNA accumulates to high levels activating the host antiviral
proteins OAS and PKR. OAS produces 2-5A, which activates RNase L,
causing degradation of viral RNA and rRNA, whereas PKR phosphorylates
eIF2a. Both pathways inhibit protein synthesis, thus preventing viral replica-
tion. The VACV E3L gene encodes two dsRNA binding proteins that reduce
PKR and OAS activation. Modified from McFadden (2005).
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either D9 or D10 has relatively
modest effects on viral repli-
cation and virulence.
In sharp contrast, one of
the new papers shows how
inactivating point mutations
in the nudix/MutT motifs of
both D9 and D10 in the
same virus (by homologous
recombination) had a dra-
matic host-range effect (Liu
et al., 2015). Plaque sizes
were greatly reduced after
infection with the D9/D10
doubly mutated virus in hu-
man and monkey cells, but
not in rodent cells. Also, viral
yields were reduced by 100-
to 1,000-fold in human and
monkey cells, with only minor
effects in rodent cells. Viral
morphogenesis too was
blocked in non-permissive
monkey cells infected with
the doubly mutated virus. In
addition, production of post-
replicative viral proteins in
response to the double D9/
D10 mutant VACV was
severely inhibited in the mon-
key and human cells, but not
in the rodent cell types.
Notably, in monkey cells,
infection with the D9/D10
mutant VACV produced
prominent and massive deg-
radation of rRNA in intact
ribosomes into discrete
cleavage products that are
characteristic of RNase L
activity. Involvement of
RNase L was confirmed by
showing that rRNA degrada-tion was greatly decreased in cells
depleted of RNase L with shRNA. The
extent of rRNA degradation was remark-
able when compared to that typically
observed for other types of viral infec-
tions, suggesting very high levels of
dsRNA activators of OAS. Indeed,
massive accumulation of dsRNA in the
D9/D10 double mutant VACV-infected
cells was observed in the virus factories
by immunostaining with anti-dsRNA anti-
bodies. Viral RNA also appears to have
been targeted for degradation. The drug,
Ara C, which prevents viral DNA replica-
tion, blocked rRNA degradation, suggest-288 Cell Host & Microbe 17, March 11, 2015ing activation of OAS/RNase L occurred
late in the viral replication cycle, coin-
ciding with the buildup of dsRNA. Results
are consistent with a prior study that de-
tected accumulation of the OAS product,
2-5A, during VACV infections and that
was also inhibited by Ara C (Rice et al.,
1984). Phosphorylation of PKR, its sub-
strate eIF2a, and IRF3 was similarly
enhanced after infection with the double
mutant VACV, showing effects of dsRNA
accumulation on other innate immunity ef-
fectors. Finally, the D9/D10 double
mutant VACV was greatly attenuated in a
respiratory infection mouse model. Thereª2015 Elsevier Inc.was little or no effect on body
weight after infection even at
a high dose (106 pfu) of the
double mutant virus. Virus
replication in the lung was
also impaired after intranasal
infection with the doubly
mutated VACV.
Remarkably, VACV D9 and
D10 proteins depend on (or
co-opt) the host mRNA decay
enzyme, Xrn1, to reduce
levels of dsRNA, thereby pre-
venting OAS/RNase L and
PKR from spoiling the party
(Burgess and Mohr, 2015)
(Figure 1). Xrn1 was previ-
ously identified in a high-
throughput RNAi screen for
genes that affected VAVC
replication and spread (Sivan
et al., 2013). In the present
study, depletion of Xrn1 with
siRNA in primary human fibro-
blasts greatly reduced VACV
growth, up to 500-fold, while
also suppressing viral pro-
tein synthesis (Burgess and
Mohr, 2015). In contrast,
there was no obvious effect
of Xrn1 depletion on cellular
protein synthesis in mock-
infected or UV-inactivated
VACV-infected cells. Knock-
down of Xrn1 together with
mutation of D9 (but not
D10) caused nearly complete
inhibition of viral protein
synthesis. Polyphonoacetate,
an inhibitor of viral DNA
synthesis, prevented the in-
hibitory effect of depleting
Xrn1 on protein synthesis,
implicating a late event in theviral replication cycle. Similarly, deletion
of intermediate transcription factor A23
required for intermediate and late viral
transcription negated the effect of Xrn1
on protein synthesis.
VACV encodes two types of proteins
that should in principle prevent activation
of PKR and OAS/RNase L, E3L and K3L.
K3L is a pseudosubstrate inhibitor of
PKR, while E3L sequesters dsRNA inhibit-
ing both PKR and OAS (Langland and Ja-
cobs, 2002) (Figure 1). E3L and K3L
expression were confirmed in control
and Xrn1-depleted cells, yet PKR and
OAS remained active during VACV
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increased rRNA cleavage by RNase L in
VACV-infected cells.
Interestingly, reversal of protein synthe-
sis inhibition was obtained by downregu-
lation of both Xrn1 and RNase L, whereas
downregulation of PKR and Xrn1 seemed
to have no effect. Why does PKR deple-
tion have no effect on protein synthesis
if eIF2a is phosphorylated? The explana-
tion seems to be that RNase L activity is
dominant over PKR in restricting protein
synthesis in the VACV model, but this
may depend on different levels of the
dsRNA sensors, OAS and PKR, in
different cell types (Langland and Jacobs,
2002; Zhao et al., 2013). Immunostaining
of cells with monoclonal antibody against
dsRNA showed enhanced accumulation
of dsRNA in viral factories in VACV-in-
fected cells when Xrn1 is depleted
(Burgess and Mohr, 2015) (similar to the
effects of double D9/D10 mutations [Liu
et al., 2015]). Levels of select viral early
mRNAs were increased in Xrn1-depleted,
VACV-infected cells, suggesting that viral
dsRNA is produced from annealing of
complementary viral transcripts (Burgess
and Mohr, 2015). Surprisingly, Xrn1
depletion enhanced activation of PKR
and inhibition of protein synthesis in pri-
mary human fibroblasts transfected with
synthetic dsRNA, poly(rI):poly(rC)
(Burgess and Mohr, 2015). These findings
suggest a possible larger role for Xrn1 in
limiting dsRNA accumulation in cells in-
fected with other types of viruses.Together, these two reportssuggest that
D9/D10andXrn1 limit accumulationof viral
dsRNA by decapping and degrading viral
mRNAs as single-stranded RNAs prior to
annealing into dsRNA and/or by acting on
dsRNA per se (Burgess and Mohr, 2015;
Liu et al., 2015) (Figure 1). In the case of
intact dsRNA, its degradation might
require involvement of an RNA helicase in
addition to a decapping enzyme and Xrn1
(Jones et al., 2012). Either elimination of
D9 and D10 or RNAi depletion of Xrn1
have similar effects, likely due to extending
half-lives of complementary viral mRNA
that anneal into dsRNA. The fact that
VACV encodes two VACVmRNA decapp-
ing enzymes (D9 andD10), and twodsRNA
binding proteins (E3L) (Langland and Ja-
cobs, 2002), indicates the magnitude of
the threat to the virus that exposed dsRNA
poses. In addition to activating OAS/
RNase L and PKR, dsRNA is also a major
pathogen-associated molecular pattern in
type I IFN induction through the RIG-I like
receptors. Another major finding is that
Xrn1 is identified as a host factor capable
of negatively regulating the antiviral
response. One ‘‘take-home’’ message
from these papers is that viral proteins
that sequester dsRNA, such as E3L, are
sometimes insufficient to completely block
OAS/RNase L and PKR. Back-up path-
ways to eliminate or prevent formation of
dsRNA such as those described in these
two papers are then necessary if the virus
is to replicate and spread effectively. One
of these papers also suggests that target-Cell Host & Microbe 1ing Xrn1 with a drug might lead to antiviral
activity (Burgess and Mohr, 2015), while
the other paper shows that the D9/D10
double mutant VACV elicits a protective
immune response against a pathogenic
VACV (Liu et al., 2015).REFERENCES
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